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Introduction: Gallbladder cancer (GBC) is the ﬁfth most common neoplasm of the gastrointestinal tract
and the most common cancer of the biliary tract. GBC is suspected preoperatively in only 30e40% of
patients. The other 60e70% are discovered incidentally (IGBC) by the pathologist on a gallbladder
specimen following cholecystectomy for benign diseases such as polyps, gallstones, and cholecystitis.
Materials and methods: Between 1995 and 2011, 30 cases of GBC, who underwent resection with
curative intent in our institutions, were retrospectively reviewed. They were analyzed for demographic
data, and type of operation, surgical morbidity and mortality, histopathological classiﬁcation, and sur-
vival. Incidental GBC was compared with suspected or preoperatively diagnosed GBC. Overall survival,
disease-free survival (DFS) and the difference in DFS between patients previously treated with laparo-
scopic cholecystectomy and those who had oncological resection as ﬁrst intervention were analyzed. The
authors also present a systematic review to evaluate the role of extended surgery in the treatment of the
incidental GBC. Results: GBC was diagnosed in 30 patients, 16 women and 14 men. The M/F ratio was
1:1.14 and the mean age was 69.4 years (range 45e83 years). A preoperative diagnosis was possible only
in 14 cases; fourteen of the incidental cases were diagnosed postoperatively after the pathological ex-
amination; two were suspected intraoperatively at the opening of the surgical specimen and then
conﬁrmed by frozen sections. The ratio between incidental and nonincidental cases was 1, 14/1, with
twelve cases discovered after laparoscopic cholecystectomy. Eighty-one per cent of the incidental cases
were discovered at an early stage (II). The preoperative diagnosis of the 30 patients with GBC was: GBC
with liver invasion diagnosed by preoperative CT (nine cases); gallbladder abscess perforated into he-
patic parenchyma and involving the transversal mesocolon and hepatic hilum (one case); porcelain
gallbladder (three cases); gallbladder adenoma (four cases); and chronic cholecystolithiasis (thirteen
cases). Every case, except one, with a T1b or more advanced invasion underwent IVb þ V wedge liver
resection and pericholedochic/hepatoduodenal lymphoadenectomy. One patient refused further surgery.
Cases with Tis and T1a involvement were treated with cholecystectomy alone. Nine of the sixteen pa-
tients with incidental diagnosis reached 5-year DFS (56.25%) and eight of them are recurrence free.
Surprisingly, one patient reached 38 mo survival despite a port-site recurrence (the only one in our
experience) 2 years after the original surgery requiring further resection. Cases with non incidental
diagnosis were more locally advanced and only two patients experienced 5 years DFS (Tables 2 and 3).vallaro), schaky@hotmail.it (G. Piccolo), divitama@unict.it (M. Di Vita), amzanghi@unict.it (A. Zanghì), f.cardi@unict.it
la.borzi@yahoo.it (L. Borzì), panebianco.vincenzo@virgilio.it (V. Panebianco), idicarlo@unict.it (I. Di Carlo),
nict.it (A. Cappellani).
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GBCA, GBC, GC gallbladder cancer
IGBC incidental gallbladder cancer
DFS disease free survival
OS overall survival
R0 no microscopic residual diseas
AJCC American Joint Committee on
PLNC number of positive nodes
PSE port site excisionConclusion: Laparoscopic cholecystectomy does not affect survival if implemented properly. Reoperation
should have two objectives: R0 resection and clearance of the lymph nodes.
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Cancer1. Introduction
Gallbladder cancer (GBC) is the ﬁfth most common neoplasm of
the gastrointestinal tract and the most common cancer of the
biliary tract. The prognosis is usually dismal because of the
aggressive nature of GBC: 5-year survival rates range from 5 to 20%
[1]. Most patients present with advanced disease, therefore are not
candidates for curative resection. For those patients that undergo
resection, long-term survival is possible but the recurrence rate is
considerable [1e5].
GBC is suspected preoperatively in only 30% of patients. The
other 70% are discovered incidentally (IGBC) by the pathologist on a
gallbladder specimen following cholecystectomy for benign dis-
eases such as polyps, gallstones, and cholecystitis [1e4].
IGBC is discovered in 0.20e3% of all cholecystectomies. With
greater availability of ultrasonography, cholecystectomy has
become the commonest surgical procedure performed worldwide.
As a result of this, we expect over time an increase of the number of
patients with incidentally discovered gallbladder cancer[ [1,6e9].
The R0 surgical resection is the mainstay of GBC therapy:
additional resection, aimed to the absence of residual disease, is
considered to offer better survival. Patients who undergo re-
resection demonstrate a 5-year survival ranging from 0 to 100%
with a close relation to the GBC stage. Simple cholecystectomy may
be adequate treatment only for the earlier stages: Tis and T1a
[1,3e5,8,10]
Re-resection (including radical cholecystectomy with regional
lymphadenectomy) is recommended for T1b and later stage carci-
nomas as long as the disease appears to be R0 resectable
[1,3e5,8,11].
The management of IGBC is difﬁcult because no guidelines have
been established. Some technical controversies (extent of hepa-
tectomy, role of lymphadenectomy, bile duct resection and port-
site excision) are, still today, unsolved [1e8]. Moreover some au-
thors have reported worse overall prognosis when the patient was
not adequately treated during the ﬁrst operation.
We report our experience (30 cases) in the treatment of GBC,
and present a systematic review to evaluate the role of extended
surgery in the treatment of the incidental GBC.
A Medline search was performed using the keywords “Inci-
dental gallbladder cancer”, “laparoscopic cholecystectomy”,
“lymph nodes dissection” and “hepatic resection”.Reviewing the literature, we focused on the following key
points, which are still considered controversial in the management
of GBC:
1 - presentation, outcome, and management of incidentally
discovered gallbladder cancer
2 - extent of hepatic resection
3 - extent of lymph node dissection, number of nodes and
lymphnode ratio
4 - resection of the common bile duct
5 - surgical strategy related to depth invasion
6 - meaning of port-site metastases and peritoneal disease
7 - laparoscopy þ re-resection vs one stage approach
8 - contraindications to the surgical treatment and combined
multiorgan resections.2. Materials and methods
2.1. Data collection
From 1995 to 2011, 30 cases of GBC who underwent resection
with curative intent, in the Department of General Surgery e Uni-
versity of Catania, were retrospectively reviewed.
Patients demographic data, surgical procedures, postoperative
outcomes (surgical morbidity and mortality), histopathological
classiﬁcation, and survival data were collected in a database for
further analysis. The diagnosis of gallbladder pathology was made
by history, physical examination, and laboratory and imaging
studies [ultrasonography and computed tomography (CT)].
2.2. Disease-free survival (DFS) analysis
The patients were divided in two groups: incidental diagnosis of
gallbladder carcinoma, and known or suspected diagnosis preop-
eratively. The primary endpoint of the study was DFS at different
stages of diagnosis. The secondary endpoint was the difference in
DFS between patients previously treated with laparoscopic chole-
cystectomy and patients who had oncological resection as their ﬁrst
intervention. The results are reported in percentages and means.
3. Results
GBC was diagnosed in 30 patients, 16 women and 14 men. The
M/F ratio was 1:1.14 and themean agewas 69.4 years (range 45e83
years).
A preoperative diagnosis was possible only in 14 cases; fourteen
of the incidental cases were diagnosed postoperatively after the
pathological examination; two were suspected intraoperatively at
the opening of the surgical specimen and then conﬁrmed by frozen
sections.
The ratio between incidental and total cases was 16/30.
According to TNM staging of the 7th edition of the AJCC, our
patients were divided into: pTis (2), pT1a (3), pT1b (6), pT2 (11),
pT3 (6), pT4 (2).
According to TNM staging of the 7th edition of the AJCC, nine
cases were Stage I (T1N0); ﬁve cases were Stage II (T2 N0); two
were Stage IIIa (T3 N0); eight with Stage IIIb (T1eT3 N1); one with
A. Cavallaro et al. / International Journal of Surgery 12 (2014) S108eS119S110Stage IVA (T4 N1); three with Stage IVB (any T, N2 or M1); two with
Stage 0.
Eighty-one per cent of the incidental cases were discovered at
an early stage (II). The ratio between incidental and nonincidental
cases was 1,14/1, with twelve cases discovered after laparoscopic
cholecystectomy. The preoperative diagnosis of the 30 patients
with GBC was: GBC with liver invasion diagnosed by preoperative
CT (nine cases); gallbladder abscess perforated into hepatic pa-
renchyma and involving the transversal mesocolon and hepatic
hilum (one case); porcelain gallbladder (three cases); gallbladder
adenoma (four cases); and chronic cholecystolithiasis (thirteen
cases).
Pathological characteristics of the tumors were: ﬁve well-
differentiated polypoid adenocarcinoma (G1); two well-
differentiated non-polypoid adenocarcinoma of the gallbladder
fundus (G1); two moderately differentiated nonpolypoid and six
moderately differentiated polypoid adenocarcinoma (G2); four G2-
G3 differentiated polypoid and one G2-G3 non polypoid adeno-
carcinoma; and two and eight polypoid and nonpolypoid poorly
differentiated GBC (G3), respectively (Table 1).
Two lesions were “in situ” cancer.
Every case, except one, with a T1b or more advanced invasion
underwent IVb þ V wedge liver resection and pericholedochic/
hepatoduodenal lymphoadenectomy. One patient refused further
surgery. Cases with Tis and T1a involvement were treated with
cholecystectomy alone.
One incidental case was diagnosed by intraoperative frozen
section and treated accordingly with one stage procedure. One
more case, diagnosed by intraoperative frozen section, was surgi-
cally treated later because of the need of a more accurate staging.
Nine of the sixteen patients with incidental diagnosis reached 5-
year DFS (56.25%) and eight of them are recurrence free. Surpris-
ingly, one patient reached 38 mo survival despite a port-site
recurrence (the only one in our experience) 2 years after the orig-
inal surgery requiring further resection. Cases with nonincidental
diagnosis were more locally advanced and only two patients
experienced 5 years DFS (Tables 2 and 3).Table 1
Patient characteristics with GBC n (%).
No. of patients
30
IGBC
16
NIGBC
14
Polyposis lesions 11 (68.7) 6 (42.8)
Nonpolyposis lesions 5 (31.2) 8 (57.1)
Histopathological grade
G1 6 (37.5) 1 (7.1)
G2 or G2eG3 9 (56.25) 4 (28.5)
G3 1 (6.2) 9 (64.28)
Lymphatic invasion
þ 5 (31.2) 8 (57,1)
 11 (68,7) 6 (42.8)
Vessel invasion
þ 2 (11.1) 4 (10)
 14 (88.9) 10 (90)
Perineural invasion
þ 2 (12.5) 5 (35.7)
 14 (87.5) 9 (64.28)
Stage VII Ed.
0 2 (12.5) 0
I 7 (43.7) 2 (14.28)
II 4 (25.0) 1 (7.1)
IIIA 0 2 (14.2)
IIIB 2 (12.5) 6 (42.8)
IVA 0 1 (7.14)
IVB 1 (6.2) 2 (14.2)
IGBC: Incidental gallbladder cancer; NIGBC: Nonincidental gallbladder cancer.4. Discussion
4.1. Presentation and outcome
Given that cholecystectomy for gallstone disease is the second
or the third most frequent procedure in digestive surgery, inci-
dental GBC is going to become an increasingly frequent medical
entity.
The widespread use of laparoscopic cholecystectomy has led to
discovery of this deadly disease at an earlier stage, altering the
management and the outcome of these patients. GBC is an inci-
dental ﬁnding in 0.25e3% of patients and almost half of these cases
are occasionally discovered during or after laparoscopic cholecys-
tectomy for benign disease, such as gallstones and their compli-
cations [47% in the series of Memorial SloaneKettering Cancer
Centre (MSKCC), 50% in the series of Johns Hopkins] [2,4]. The
earlier discovery results in an earlier pathological stage, and
consequently, increased long-term survival [4,6e9]. Patients with
incidental GBC had a signiﬁcant increase in survival when
compared with those who had a preoperative diagnosis (overall 5-
year survival 15% vs 33%) [2,4].
Therefore, the general surgeon should be prepared to deal with
GBC suspected or diagnosed incidentally, following a well-
established treatment algorithm [5e8].
It is paramount not to violate oncological principles during the
ﬁrst operation, if a two-stage approach is necessary. For this reason,
the surgeon during a laparoscopic cholecystectomy should always
follow these simple rules:
- perform an accurate preoperative diagnosis;
- preserve the integrity of the gallbladder
- use the endobag for the removal of the gallbladder
- when in doubt, give up the laparoscopy to open access
- carefully inspect the gallbladder once extracted
- perform a histological examination impromptu;
- desufﬂate the pneumoperitoneum with the trocars in situ
During cholecystectomy, accidental opening of the gallbladder is
described in 25e30% of the cases, which clearly have a worse
prognosis [3,5,9,12].
4.2. Management
The prognosis strongly depends on the stage and on the possi-
bility of achieving R0 oncological resection [2e4,12,13].
Patients with IGBC can be divided into two clinical groups:
1. Patients with GBC discovered during cholecystectomy for
assumed benign disease.
2. Patients with GBC diagnosed histo-pathologically after chole-
cystectomy for benign disease.
All gallbladders removed for stone disease should always be cut,
opened and examined carefully for any suspicious lesions before
closing incision. If suspicious lesion is present, the gallbladder
should be sent for a timely frozen section for diagnosis and
assessment of depth of invasion. If the surgeon is trained, and the
team has experience in the management of hepatobiliary disease,
radical cholecystectomy should be done. If not, the abdomen
should be closed and patient should be referred to a higher centre
for radical surgery.
When incidental GBC is diagnosed afterward by the pathologist,
the surgical specimen or blocks should be carefully studied for
identiﬁcation of the depth of invasion (T stage), grade and location
of the tumor (liver side/free peritoneal side/infundibulum),
Table 2
Demographic and clinical data.
Patient G Age Incidental TNM 7th ed. Stage 7th ed. Cystic d. Res. Size Grade Lymph Vessel Perineural 5-year survival
A.P M 63 No pT2 N1 Mx IIIB R0 R0 10 (NP) G3 No No No alive, 38 mo
S.A F 82 No pT4 N2 M1 IVB R0 R1 45 (NP) G3 Yes Yes Yes dead, 3 mo
C.I F 60 No pT3 N1 Mx IIIB R1 R1 60 (P) G3 No No Yes dead, 6 mo
S.L F 72 No pT3 N1 Mx IIIB R0 R1 32 (NP) G3 Yes No No dead, 8 mo
P.G M 76 No pT4 N1 Mx IVA R0 R1 49 (NP) G3 Yes No Yes dead, 7 mo
G.F M 81 No pT3 N0 Mx IIIA R0 R1 44 (NP) G3 No No No dead, 9 mo
P.C F 77 No pT2 N0 Mx II R0 R0 20 (P) G2 No No No dead, 24 mo
C.M F 45 No pT1a N0 Mx I R0 R0 25 (P) G1 No No No alive, no recurrence at 7 years
S.G M 81 No pT3 N1 Mx IIIB R0 R1 24 (P) G2 Yes No No dead, 28 mo
R.M F 66 No pT1b N0 Mx I R0 R0 07 (P) G2 No No No alive, no recurrence at 6 years
S.V F 69 No pT3 N2 Mx IVB R0 R1 30 (P) G3 Yes Yes Yes dead, 7 mo
A.F M 64 No pT3 N0 Mx IIIA R0 R0 35 (NP) G3 Yes Yes Yes dead 23 mo
F.Z. F 77 No pT2 N1 Mx IIIB R0 R0 45 NP G2-G3 Yes No No alive, no recurrence at 4 years
T.R. M 76 No pT2 N1 Mx IIIB R0 R0 28 (NP) G3 Yes Yes No dead 18 mo
C.C F 73 Yes pT2 N0 Mx II R0 R0 19 (NP) G3 Yes Yes No alive, recurrence at 19 mo
R.C M 69 Yes pT1b N0 Mx I R0 R0 15 (NP) G1 No No No alive, 38 mo (disease recurrence)
C.M M 65 Yes PT1a Nx Mx I R0 R0 18 (P) G1 No No No alive, no recurrence at 7 years
T.F F 72 Yes pT2 N0 Mx II R0 R0 10 (NP) G2 No No No alive, no recurrence at 7 years
G.G M 55 Yes pT2 N0 M1 IVB R1 R1 30 (P) G2-G3 No Yes Yes dead, 08 mo
M.P F 78 Yes pT2 N1 Mx IIIB R0 R1 14 (P) G2-G3 Yes No No dead, 26 mo
S.G F 57 Yes pT1b N0 Mx I R0 R0 30 (P) G2-G3 No No No alive, no recurrence at 7 years
P.A M 71 Yes pT2 N1 Mx IIIB R0 R0 20 (P) G2-G3 Yes No No dead, 23 mo
C.A F 67 Yes pTis Nx Mx 0 R0 R0 06 (NP) G1 No No No alive, no recurrence at 13 mo
S.I. F 63 Yes pT2 N0 Mx II R0 R0 14 (NP) G2 Yes No No alive, no recurrence at 5 years
T.R M 68 Yes pT1b N0 Mx I R0 R0 15 (P) G2 No No No alive, no recurrence at 6 years
G.B F 72 Yes pT2 N0 Mx II R0 R0 25 (P) G2 Yes No Yes alive, no recurrence at 6 years
A.G M 83 Yes pT1b N0 Mx I R0 R0 10 (P) G1 No No No alive, no recurrence at 8 years
C.F M 70 Yes pT1a Nx Mx I R0 R0 04 (P) G1 No No No alive, no recurrence at 7 mo
P.R F 61 Yes pTis Nx Mx 0 R0 R0 12 (P) G1 No No No alive, no recurrence at 7 years
C.R M 69 Yes pT1b Nx Mx I R0 R0 05 (P) G2 No No No dead, 6 years 6 mo
69.4
Stage T N
0 Tis N0
I T1 N0
II T2 N0
IIIA T3 N0
IIIB T1e3 N1
IVA T4 N0e1
IVB Any T N2
Any T Any N
Reprinted with permission from AJCC: Gallbladder. In: Edge SB, Byrd DR, Compton CC et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 211e7.
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margin, or cystic duct node involvement [2e4,9,10e13].
Contrast enhanced triphasic computed tomography (CT) scan/
Magnetic resonance imaging (MRI) are essential to restage the
patients. Positron emission tomography and computed tomogra-
phy (PETeCT) does not have a role in routine imaging in GBC but
they could help to detect unsuspected metastasis, regional
lymphadenopathy, peritoneal metastasis, residual disease in gall-
bladder bed (post cholecystectomy), metastasis in the oriﬁces of
the trocars [14,15].
Adopting an iterative approach, the surgeon will also be able to
providemore detailed information to the patient and obtain a more
accurate informed consent to the resective procedure thus avoiding
the risk of infringing the rights of self-determination of the patient
(Fig. 1).
Nowadays, reoperation for incidental GBC should have two
fundamental objectives: R0 resection of the liver parenchyma with
the other adjacent structures, and clearance of the locoregional
lymph nodes [2e4,7,8].4.2.1. Extent of liver resection during reoperation
Although simple cholecystectomy appears to be an adequate
treatment for Tis/T1a tumors, for tumors with extension deeperthan the lamina propria (T1b), radical re-resection with regional
lymphadenectomy has been advocated.
Re-resection, including liver resection, should be performed in
these patients because most (56e60%) had residual tumor at the
time of re-operation. Furthermore, the presence of residual tumor
was found to be an important predictor of survival [2e4,6e16].
Hepatic resection for GBC has two main purposes: resect the
tumor that has directly invaded the liver from the gallbladder bed,
and prevent micrometastases that may recur around the gall-
bladder bed. Onemore purpose could be to resect en block Glisson's
sheath of the right lobe of the liver because of potential invasion of
hepatoduodenal ligament [3e16].
Generally, operative procedures for incidental GBC include:
extended cholecystectomy or Glenn resection (i.e. cholecystectomy
plus partial resection of liver segments 4 and 5, approximately
2e3 cm from the gallbladder bed); anatomic resection of liver
segment 5 and lower part of segment 4 when GC invades the liver
bed to a depth of 2 cm or more; right hepatectomy when GC
invaded the right Glisson capsule [3,7,8].
Although several authors have emphasized that the extent of
the surgery needed to treat GBC seems to depend on the depth of
the tumor, as noted in the literature, the preference today is for
parenchyma-sparing operations, such as no anatomical wedge
resection [1,3].
Table 3
Surgical data.
Patient G Age Incidental TNM 7th
ed.
Stage 7th
ed.
Cystic
d.
Res. Surgery 5-year survival
A.P M 63 No pT2 N1 Mx IIIB R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) alive, 38 mo
S.A F 82 No pT4 N2 M1 IVB R0 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) þ VBP res dead, 3 mo
C.I F 60 No pT3 N1 Mx IIIB R1 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 6 mo
S.L F 72 No pT3 N1 Mx IIIB R0 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 8 mo
P.G M 76 No pT4 N1 Mx IVA R0 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 7 mo
G.F M 81 No pT3 N0 Mx IIIA R0 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 9 mo
P.C F 77 No pT2 N0 Mx II R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 24 mo
C.M F 45 No pT1a N0
Mx
I R0 R0 cholecystectomy, no further surgery alive, no recurrence at 7
years
S.G M 81 No pT3 N1 Mx IIIB R0 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 28 mo
R.M F 66 No pT1b N0
Mx
I R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) alive, no recurrence at 6
years
S.V F 69 No pT3 N2 Mx IVB R0 R1 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead, 7 mo
A.F M 64 No pT3 N0 Mx IIIA R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead 23 mo
F.Z. F 77 No pT2 N1 Mx IIIB R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) alive, no recurrence at 4
years
T.R. M 76 No pT2 N1 Mx IIIB R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) dead 18 mo
C.C F 73 Yes pT2 N0 Mx II R0 R0 wedge res. (IVb þ V) þ lymphadenectomy (I stage) alive, recurrence at 19 mo
R.C M 69 Yes pT1b N0
Mx
I R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II
stage) þ PS exc
alive, 38 mo (disease
recurrence)
C.M M 65 Yes PT1a Nx
Mx
I R0 R0 cholecystectomy alive, no recurrence at 7
years
T.F F 72 Yes pT2 N0 Mx II R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II
stage) þ PS exc
alive, no recurrence at 7
years
G.G M 55 Yes pT2 N0 M1 IVB R1 R1 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II
stage) þ VBP
dead, 08 mo
M.P F 78 Yes pT2 N1 Mx IIIB R0 R1 cholecystectomy, refused further surgery dead, 26 mo
S.G F 57 Yes pT1b N0
Mx
I R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II
stage) þ PS exc
alive, no recurrence at 7
years
P.A M 71 Yes pT2 N1 Mx IIIB R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II
stage) þ PS exc
dead, 23 mo
C.A F 67 Yes pTis Nx Mx 0 R0 R0 LC alive, no recurrence at
13 mo
S.I. F 63 Yes pT2 N0 Mx II R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II stage) alive, no recurrence at 5
years
T.R M 68 Yes pT1b N0
Mx
I R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II stage) alive, no recurrence at 6
years
G.B F 72 Yes pT2 N0 Mx II R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II stage) alive, no recurrence at 6
years
A.G M 83 Yes pT1b N0
Mx
I R0 R0 LC (I stage) e wedge res. (IVb þ V) þ lymphadenectomy (II stage) alive, no recurrence at 8
years
C.F M 70 Yes pT1a Nx
Mx
I R0 R0 LC alive, no recurrence at 7 mo
P.R F 61 Yes pTis Nx Mx 0 R0 R0 LC alive, no recurrence at 7
years
C.R M 69 Yes pT1b Nx
Mx
I R0 R0 cholecystectomy, refused further surgery dead, 6 years 6 mo
M/F 14/
16
69
Stage T N M
0 Tis N0 M0
I T1 N0 M0
II T2 N0 M0
IIIA T3 N0 M0
IIIB T1e3 N1 M0
IVA T4 N0e1 M0
IVB Any T N2 M0
Any T Any N M1
Reprintedwith permission from AJCC: Gallbladder. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer StagingManual. 7th ed. New York, NY: Springer, 2010, pp 211e7.
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293 patient with pT2 gallbladder cancer and 192 with of pT3 gall-
bladder cancer.
The patients were distinguished in four groups: pT2 gallbladder
cancer group with cancer on the hepatic side, pT2 gallbladder
cancer group with cancer on the peritoneal side, pT3 gallbladder
cancer group negative for hepatic-invasion, pT3 gallbladder cancer
group positive for hepatic-invasion.The authors showed that there was no signiﬁcant differences in
cumulative survival rate and in recurrence rates in form of liver
metastasis between patients that underwent resection of the gall-
bladder bed, anatomical segmentectomy 4b þ 5 and hepatectomy
for pT2 and pT3 GBC.
Despite in the pT3 gallbladder cancer group positive for hepatic-
invasion, the recurrence in the cut end of the liver was most
common in the group that underwent resection of the gallbladder
Fig. 1. Algorithm of treatment.
A. Cavallaro et al. / International Journal of Surgery 12 (2014) S108eS119 S113bed (9.4%), the authors demonstrated that in all four groups liver
metastasis did not particularly tend to occur to segment 4a, 5.
Similarly, other authors have reported that there was no asso-
ciation between major hepatectomy and long-term survival, and
that there was an increased association between major hepatic
surgery and perioperative morbidity [1,3,4].
In order to support this, Pawlik et al. [3], in their analysis of 148
patients with incidental gallbladder adenocarcinoma, have proved
that patients who had undergone major hepatic resection
(anatomical segmentectomy of 4a þ 5 or right hepatectomy) had aFig. 2. Non-anatomical resection of hepatic parenchyma, with a distal clearance of at
least 2 cm.similar risk of speciﬁc death as patients who underwent hepatic
wedge resection, on both unvariate and multivariate analyses.
Rather than the type of hepatic resection, the surgeon's goal
should be to resect all disease with negative histologic margins, the
most important factor that determines the ﬁnal outcome. In fact,
R1/R2 margin status is associated with decreased long-term sur-
vival [17].
In conclusion, for gallbladder cancer without hepatoduodenal
ligament invasion and without any locoregional liver involvement,
the wedge resection of the gallbladder bed (2e3 cm) is preferable
to hepatectomy [3,5,17]. With regard to GBC that has invaded the
gallbladder bed, in order to obtain negative histological margins,
the preferred approach is non-anatomical resection of hepatic pa-
renchyma, with a distal clearance of at least 2 cm (Fig. 2) [3,5,17].4.2.2. Extent of lymph node dissection
Today reoperation for incidental GBC should have two funda-
mental objectives: R0 resection of the liver parenchyma with the
other adjacent structures, and clearance of the locoregional lymph
nodes [7,8].
GBC spreads through different pathways: locoregional,
lymphatic, vascular, neural, intraperitoneal or intraductal invasion.
The main lymphatic pathway of the gallbladder descends along the
common bile duct and into the periportal nodes, then to the
posterosuperior of the head of the pancreas or around the hepatic
and celiac artery, and ﬁnally to the paraaortic nodes near the left
renal vein [18e20].
Although initial nodal involvement occurred primarily in the
cystic duct or pericholedochal nodes, the pathways of lymph node
involvement from the ﬁrst site of diffusion to the hepatoduodenal
Table 4
Residual disease in the lymph nodes after re-resection for each pT (%).
pT Ogura
et al. [22]
Tsukada
et al. [18]
Foster
et al. [23]
Pawlick
et al. [3]
You
et al.
[24]
Liang
et al.
[25]
Jensen
et al. [26]
Tis
T1a 2.5% 0% 0% 0% 0%
T1b 15.5% 0% 3.8% 0% 24.4%
T1 18% 0% 12.5% 3.8% 0% 24.4%
T2 44.3% 46% 33% 31.3% 29.2% 44.9%
T3 72% 75% 45.5% 58.7% 63.7%
T4 85.36%
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highly variable [21].
In fact, GBC can spread directly to the third level of lymph nodes,
along the perivascular soft tissue (celiac, superior mesenteric artery
and the para-aortic lymph nodes), according to the three pathways
of lymphatic drainage proposed by Ito et al. [21]: cholecysto-
retropancreatic pathway (main pathway), cholecysto-celiac and
cholecysto-mesenteric pathways (accessory pathways). The inci-
dence of occult lymphatic metastasis discovered during reopera-
tion for incidental GBC can vary from 0% to 85% in relation to the
depth of organ invasion (pT).
The reported incidence of occult lymphatic metastasis by stage
is as follows: for T1a 0e2.5%, for T1b 15e25%, for T2 30e50%, for T3
45e75%, and for T4 > 85% [3,18,22e26] (Table 4).
Similarly to other cancers, lymphadenectomy not only provides
important staging information, but more importantly, may
decrease the risk of locoregional recurrence. In fact, after tumor
resection, the level of lymph node metastasis correlates with
overall prognosis within the same pT stage category [25,26].
Miyakawa et al. [27] reported 5-year survival of 60.3% for pN0 pa-
tients, 30.0% for pN1, 16.8% for pN2, and 5.9% for pN3.
Differing philosophies have previously characterized Eastern
and Western surgical school regarding the signiﬁcance of node
number or node location: nowadays some of these views are
converging.
Accuracy of nodal staging depends on a critical number of
lymph nodes analyzed; insufﬁcient number of nodes retrieved
during surgery or examined pathologically leads to underestima-
tion of disease stage (stage migration) [25,26].
The 6th edition of the American Joint Committee on Cancer
(AJCC) required at least three nodes to be examined for adequate N
staging. No mention of a minimum lymphnode number require-
ment is made in the current 7th edition.
In a cohort of 122 patients with GBCA, who underwent R0
resection at Memorial Sloan Kettering Cancer Center, the overall
survival of patients classiﬁed as N0 based on TLNC (total lymph
node count) <6 was signiﬁcantly worse than that of N0 patients
based on TLNC 6 [28]. Similar conclusions were drawn by a Jap-
anese group that retrospectively analyzed 135 patients and 2245
nodes (median of 14 nodes per patient): they support the practice
of retrieving at least six nodes to both improve staging and survival
[29].
These observations indicate that retrieval of a larger number
(6) of lymph nodes, than previously practiced, is advisable not
only for accurately staging the nodal status, but also for improving
survival due to better clearance of nodal disease.
One more emerging parameter is the involved lymph node ratio
(LNR) which ideally incorporates not only the entity and biology of
disease (PLNC e positive node count) but also the quality of lym-
phadenectomy and pathologic examination (TLNC).Lowe et al., in a study of 36 patients, found an LNR of 0.3 to be
associated with signiﬁcantly impaired prognosis. However the
prognostic value of the LNR overwhen compared to total number of
involved nodes (TLNC) remains to be shown [30].
The AJCC staging varied the node classiﬁcation over the past
three revision of the system. In the 5th edition, nodes were char-
acterized as N1 and N2 with the ﬁrst group of nodes being
considered those in the hepatoduodenal ligament up to the hepatic
artery/gastroduodenal artery junction, and those behind the
pancreas and up to the celiac axis as N2. In the sixth edition any
involved node was considered N1.
In the 7th edition, the N2 category was restored including
regional nodes in celiac, periduodenal, and peripancreatic loca-
tions, and nodes along the superior mesenteric artery: patients
within this cluster are now categorized as stage IVB [31]. The sig-
niﬁcance of node location in term of prognosis is still not clear. In a
Japanese cohort of 116 patients with GBCA undergoing R0 resec-
tion, Shirai Y et al. analyzed 2406 lymph nodes in terms of number
involved as well as anatomical location. The authors found that 5-
year survival dropped from 81% for patients with N0, to 62% for
those with a single positive node, to 43% for those with 2e3 nodes
and 15% for those with four or more nodes positive. Although the
number of positive nodes (PLNC) was an independent factor
determining prognosis, according to this study the location of
nodes was not signiﬁcant [29].
Jensen et al. examined 4614 patients, surgically treated between
1988 and 2004, from the SEER database. According to their study
only about 6% of patients with early stage GB cancer currently
receive recommended surgical therapy in the United States. Most of
them are patients with T3 cancers. This number is substantially
lower when we consider only those patients with T1B and T2
neoplasms, who undergo appropriate therapy in approximately 3%
of cases reported.
According to Jensen the lymph node evaluation is a critical
component of radical resection for GBCA, and patients who un-
derwent ‘‘radical resection’’ that did not include lymph node
assessment had no signiﬁcant improvement in overall survival
compared to patients undergoing simple cholecystectomy alone
(23 vs. 22 months) [26].
In western countries, lymphadenectomy has been usually
conﬁned to the hepatoduodenal ligament around the hilar area
(cystic, pericholedochal and hilar lymph nodes).Fig. 3. Lymphadenectomy of the hepatoduodenal ligament around the hilar area
(cystic, pericholedochal, periportal and hilar lymph nodes).
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of all nodes along the portal structures (portal vein, hepatic artery
and common bile duct), gastrohepatic ligament, retroduodenal,
peripancreatic and celiac axis lymphnodes with or without bile
duct resection (Fig. 3).
While it is not routinely advocated, the extended radical lym-
phadenectomy should be considered with T2 or more advanced
disease. The role of para-aortic nodal clearance remains unclear
[1e4,28,30].4.2.3. Resection of the common bile duct
Although many surgeons advocate routine resection of the
common bile duct at the time of curative resection, resection of the
common bile duct performed at the time of the hepatic resection
and lymphadenectomy is controversial [32,33]. GC has a strong
tendency to invade the hepatoduodenal ligament in the form of
perineural invasion or lymph node metastasis, therefore, en bloc
resection of the regional lymph nodes together with excision of the
connective tissue around the portal and hepatic artery should be
performed, whenever lymph node dissection of the hep-
atoduodenal ligament is entertained [34e36]. Shimizu et al. [10]
proposed routine resection of the extrahepatic bile duct to facili-
tate lymphadenectomy, avoiding common bile duct ischemia, and
increasing the number of lymph nodes harvested. However, these
beneﬁts have not been conﬁrmed in other studies [32,33]. Pawlik
et al. [3], in their analysis of 148 patients with incidental gallbladder
adenocarcinoma, showed that the median number of lymph nodes
harvested at the time of lymphadenectomy was the same (n ¼ 3),
regardless of whether the common bile duct was or was not
resected concomitantly with lymph node dissection.
Araida et al. [32], in the largest series to date (collated by 114
Japanese member institutions), analyzed a total of 4243 GBC pa-
tients treated between 1994 and 2003. There were 838 R0 patients
with pT2, pT3, and pT4 GBC in which there was no cancerous in-
vasion of the hepatoduodenal ligament and cystic duct in the ﬁnal
analysis. In this series, the resected and non-resected bile duct
groups did not substantially differ in terms of the 5-year cumulative
survival and local recurrence along the hepatoduodenal ligament.
Fuks et al., examining a French multicenter database, showed
that 86% of common bile duct resectionwas performedwithout any
information on the cystic duct. Their study showed not only any
differences in terms of recurrence and overall survival, but the
authors found that resection of the common bile duct was the only
risk factor for postoperative morbidity in a univariate analysis: it
only exposes patients to the potential complications of the bil-
ioenteric anastomosis.
The same conclusion was drawn in the multicenter Japanese
survey [32].
In conclusion, bile duct resection should be performed only
when the patients have a positive involvement of the cystic duct
margins, discovered either on the pathological review of the initial
cholecystectomy or through biopsy of the cystic duct at the time of
the second operation [3,32,33]. In fact, microscopic involvement of
the cystic duct margin is associated with a residual and/orTable 5
Five-year survival according to both stage of GBC and type of surgery.
Author T1a LC T1b LC T2 LC T2 extended resection
Fong et al. [36] 19% 61%
Wagholikar et al. [37] 100% 41.67%
Fong et al. [38] 20% 60%
Foster et al. [23] 100% 50% 38% 78%
Chijiiwa et al. [39] 17% 75%
LC: Laparoscopic cholecystectomy.additional disease in the common bile duct in over one-third of the
cases [32,33].
4.2.4. Type of treatment according to depth invasion
The depth of invasion of GBC dictates the extent of surgical
resection. In cases of carcinoma in situ or tumor invading the mu-
cosa (Tis and T1a), simple cholecystectomy with negative surgical
margins can be considered as curative surgery [3,4,23,37].
The 5-year survival after simple cholecystectomy is between 99
and 100% [23,37]. When the muscularis layer is involved (T1b), a
20e50% localeregional recurrence can be expected after simple
cholecystectomy [3,6,37] (Table 5). At the time of reoperation, it has
been shown that there is a 10% incidence of residual disease in the
liver bed associated with a 15e25% incidence of residual metastatic
lymph node involvement [22,24,26]. The 5-year survival after
simple cholecystectomy is between 40 and 50% [6,23,36e39].
Therefore, the recommended procedure is cholecystectomy asso-
ciated with resection of at least 3 cm of liver parenchyma (wedge
resection), plus adequate lymphadenectomy (Glenn's resection)
[37e39]. When the tumor extends beyond the serosa and invades
the liver or an organ or an adjacent structure (T3), there is a 36%
incidence of residual disease at the liver level and 45e75% inci-
dence of lymph node dissemination [5,22,25,26]. The goal of sur-
gical intervention is to obtain R0 resection, hence, mandatory steps
include extended lymphadenectomy and extended hepatic resec-
tion, associatedwith resection of other organs and structures, when
necessary (Fig. 4) [35]. T3 patients are at high risk of peritoneal
metastases, therefore, explorative laparoscopy should be consid-
ered in order to avoid unnecessary laparotomy. The 5-year survival
after simple cholecystectomy is 0e15%, and reaches 25e65% after
extended resection [5,23,36] (Table 5).
4.2.5. Port-site metastasis as expression of peritoneal disease?
Drouard ﬁrst described the development of port-site metastases
in 1991, and additional proof came in 1994 [40,41].
The prevalence of tumor seeding in port-sites after laparoscopic
cholecystectomy is very variable in published series (between 0 and
40%) with higher incidences associated with gallbladder perfora-
tion at the time of cholecystectomy [42e44]. It has been reported at
all stages of gallbladder carcinoma and at any of the trocar sites.
It generally presents after latency, ranging from a fewmonths to
3e4 years: that implies that there may be subclinical port site
disease that goes unrecognized if not resected.
The Memorial Sloan Kettering Cancer Center recently under-
lined that port-site seeding was a poor prognostic factor and
seemed associated with the existence of peritoneal carcinomatosis
and unresectable disease. [45].
The peritoneal tropism associated with gallbladder carcinoma
seems to be aggravated by the laparoscopic technique, the most
common approach for cholecystectomy today. Several mechanisms
have been suggested to explain the increased incidence: intra-
operative perforation (up to 30% of laparoscopic cholecystectomy
cases) [41e44], CO2 pneumoperitoneum, repeated passages of in-
struments through the trocars, increased abdominal pressure, tu-
moral manipulation and the relative diminution of cellular
immunity induced by pneumoperitoneum. However, inspite of
these suggested mechanisms, routine PSE after LC for GBCA con-
tinues to be an operation of unclear utility [43e49].
Some consider it a mandatory part of a deﬁnitive resection in
order to remove potential sites of tumor seeding [3,7,8], whereas
others recommend it who believe that port site disease is equiva-
lent to disseminated peritoneal disease.
The MSKCC recently published a series of 113 patients with
incidental GBCA who underwent deﬁnitive resection, from 1992 to
2009, after laparoscopic cholecystectomy or laparoscopic converted
Fig. 4. Treatment related to depth of invasion.
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exploratory laparotomy with the intent of deﬁnitive resection and
had their laparoscopic port sites resected, fourty-nine did not.
In the resected port site group, port site disease was found on
ﬁnal pathology in 13 patients (19%), all associated with T2 or T3
primary tumors. The presence of disease at port sites ﬁrmly
correlated with the development of peritoneal metastases.
Evaluating patients only after an R0 resection, peritoneal
recurrence was similar in patients after port site resection (18 of 53,
34%) and in patients who did not undergo port site resection (13 of
43, 30%, P ¼ 0.8). When only R0 resected patients were compared
and adjusted for T and N stage, there was a 31% reduction in the risk
of death, but this differencewas not signiﬁcant (P¼ 0.23), therewas
also a non signiﬁcant 11% reduction in the risk of disease recurrence
when ports were removed (P ¼ 0.69). PSE did not improve overall
survival, recurrence-free survival, or disease-speciﬁc survival in
this series. The authors therefore concluded that routine PSE was
not warranted during secondary resection of IGBC [48].
Fucks et al (2013) presented a series of 148 patients, identiﬁed in
a French multicenter database, who underwent a re-operation for
resection with curative intent for IGBC. Of these 148 patients, 54
(36%) had PSE while 94 patients (64%) did not (NPSE).
The primary endpoint was to assess the value of PSE during
secondary resection with regard to short-term (speciﬁc complica-
tions) and long-term (speciﬁc complications, recurrence, overall
survival) outcome. The incidence of port-site involvement in pa-
tients was 2%. Eight percent of patients developed incisional hernia
at the port-site after excision.
PSE did not improve the overall survival (77%, 58%, 21% at 1, 3, 5
years, respectively) compared to patients with no PSE (78%, 55%,
33% at 1, 3, 5 years, respectively, P ¼ 0.37). Among the patients
undergoing R0 resection, PSE did not improve survival (79%, 60%,
24% vs. 82%, 63%, 35% respectively, P ¼ 0.29). In the PSE group, 35%
of patients had a recurrence, comparable to the 39% of patients withrecurrence in the group without PSE: overall survival and disease
free survival were not modiﬁed by PSE [49].
According to some authors, despite there has not been a marked
change in the number of caseswith port sites resected over the years,
there has been a mildly decreasing trend in the recent era: the inci-
dence of port site disease may have been impacted by the increased
use of endo-bags, and desufﬂation procedure with trocar in site [21].
Nowadays PSE is left to the surgeon's experience and is not
performed routinely. Likewise, the technique of PSE is difﬁcult and
not standardized. Trocar are often inserted with an oblique direc-
tion: by centering the procedure only on cutaneous scar may pre-
lude to residual disease on peritoneal side. Fucks et al. suggests the
use of thin drain trocar joining the scars on the skin and peritoneal
side, to guide the resection.
In conclusion, considered the risk of incisional hernia, frozen
section of the peritoneum surrounding the peritoneal scars could
help the surgeon to identify which patients could beneﬁt from the
PSE [49].
4.2.6. Re-resection vs one stage surgery
Laparoscopic cholecystectomy, if correctly performed, did not
inﬂuence the long-term prognosis of early stage tumors (T1a, T1b,
T2) [7,8]. Also, radical re-resection, performed several months after
laparoscopic cholecystectomy, has similar results to radical resec-
tion in one stage, and long-term survival can be achieved in tumors
with inﬁltration of the liver in patients who have previously un-
dergone noncurative surgery [1,7,8,23]. Survival is strictly related to
the depth of parietal invasion of the tumor, but there is no signif-
icant difference between patients with incidental GBC discovered
during or after cholecystectomy (P ¼ 0235) [7].
4.2.7. Contraindications to additional radical resection
The only contraindication to additional surgery is the inability to
obtain radical R0 resection. In particular, the presence of peritoneal
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ease (according to the 7th edition of AJCC staging), lymph node
invasion along celiac and mesenteric vessels are commonly
considered contraindications to radical resection [35,50e52]. On
the other hand, the presence of peripancreatic (head only) lymph
node disease is not a contraindication to surgical excision, and
radical lymphadenectomy and pancreaticoduodenectomy can be
carried out together with liver resection [35,52]. Also, the depth of
liver involvement and multiorgan locoregional involvement do not
represent a contraindication for additional radical resection [50,51].
Combined pancreaticoduodenectomy, right hemicolectomy and
major hepatectomy are effective treatment for GBC with direct in-
vasion of the adjacent organs (stomach, duodenum, pancreas, colon
and liver), but only if potentially curative resection (R0) is feasible.
In these cases of multiorgan resection for GBC, given radical R0
resection, the long-term survival will depend on bile duct
involvement [35,50e52]. In fact, stromal invasion of the extrahe-
patic bile ducts is sometimes a prelude to hepatoduodenal ligament
involvement, and is also associated with a higher rate of metastases
to para-aortic nodes with a high incidence of residual tumor and
poor outcome after surgery [32].
5. Conclusion
In conclusion, incidental carcinoma of the gallbladder, as our
experience conﬁrms, generally is diagnosed at an earlier stage and
carries a better prognosis than non-incidentally found cancer.
Laparoscopic cholecystectomy does not affect survival if imple-
mented with proper technique [53e56]. Simple cholecystectomy
may be an adequate treatment only for earlier stage GBC: Tis and
T1a. All other stages, starting from T1b should be treated with hilar,
pericholedocal, periportal lymphadenectomy, lymphadenectomy of
the hepatoduodenal ligament and resection of at least 2e3 cm of
liver parenchyma around the liver bed, provided that no residual
microscopic cancer (R0) remains. Resection of the main bile ducts
could be necessary in hilum-type cancers with positive margins of
the cystic duct [57,58]. More extensive liver resection or perfor-
mance of multiorgan resection can be pursued in order to achieve
R0 resection [59e61].
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